Laurent Audoly, PhDCEO, Founder at Parthenon Therapeutics
Laurent Audoly is a serial biotech entrepreneur and senior executive in the industry. Laurent has led and/or contributed to the identification and development of seven novel medicines (Xeljanz®, Hemangiol®, Javlor®, Renflexis®, Brenzys®, Ontruzant®, Hadlima® - biologics and small molecules) addressing unmet medical need across multiple disease areas that generate > $2B in annual sales. Laurent has also led business and R&D functions in both pharma and biotech (US and EU), developing and operationalizing strategies, modernizing pipelines and business models, bringing forward drug candidates into and through development, and partnering on multiple deals (buy and sell-sides, >$3B in total). He also serves as an independent board member in different organizations (Cytovia Therapeutics, Vanderbilt University). Laurent’s latest biotech, Parthenon Therapeutics, operates at the intersection of systems biology, machine learning, molecular pharmacology, and drug development to find cures for recalcitrant cancers by reprogramming cellular pathways. Prior to founding Parthenon Therapeutics, Laurent was at the helm of Kymera Therapeutics as its founding CEO, President, and Director where he led the construction of the business, bringing in over $135M in funding and executing on > $1B in pharma partnership. Prior to this role, he was head of R&D with Fabre Pharmaceuticals (multinational pharma with $3B in top line), where he rebuilt the organization, led the in/out-licensing of multiple clinical stage assets and technologies, and directly contributed to IND entries, POC and LCM studies in oncology, dermatology, and CNS. Earlier in his career, Laurent held positions of increasing leadership responsibilities on the business and science fronts at Pfizer, Merck, MedImmune, and Pieris contributing to the advancement of 21 drug candidates into clinical development across multiple disease areas and modalities. He is also an inventor, has served on NIH study sections, and co-authored over 70 papers and patents. He studied chemistry (B.S. honors) and pharmacology (Ph.D.) at Vanderbilt University and was the recipient of an American Heart Association Fellowship at Duke University.